glp-1 receptor agonist function GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

Brasil Kidney effects of Glucagon Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective Kidney effects of Glucagon Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective Retatrutide: Phase 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Investigational Triple Agonist Retatrutide, a GIP, GLP 1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double blind, placebo and active controlled, parallel group, phase 2 trial conducted in the USA The Lancet Trends in the Development of GLP 1 Receptor Agonists NEW EPISODE: RetatrutideThe Triple Agonist *Not licensed* Will this replace the current GLP 1 in the market. This triple receptor agonist (GIP GLP 1 glucagon) is showing unprecedented results in weight loss trials, outperforming current GLP 1 medications like Ozempic, Wegovy and Mounjaro are changing diabetes and weight management, but they aren't recommended during pregnancy or while nursing. The current recommendation is to stop before conception and discuss